The pharmacokinetic parameters of colistin were comparable to those reported in previous studies in critically ill patients. However, the recommended dose may be inadequate to maintain the C(max)/MIC ratio to an optimal level-at least in patients infected with Pseudomonas spp. The dose recommendation should be based only on creatinine clearance and not body weight.

Both the capecitabine tablet formulations demonstrated equivalent rate and extent of systemic absorption, and hence were considered bioequivalent. Therefore, the two formulations can be considered as equivalent in terms of pharmacokinetics and safety profiles.

No abstract

other reasons, a prolonged prospective study to examine this issue has been impossible. It must be said, however, that clinical interest in withdrawal problems after cessation of clonidine therapy coincided with increased interest generally in problems provoked by sudden cessation of therapy. Clonidine's condemnation on these grounds may therefore owe as much to coincidence as to logic. This drug's place in modern treatment for hypertension is, of course, limited by side effects mentioned by Dr Bannan and others and the uncertainty about withdrawal, but perhaps it is time to propose a fresh look at its potential role.

No abstract